APO Research
Talk to an analyst

APO RESEARCH · REPORT

Ulcerative Colitis Drugs

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Ulcerative Colitis Drugs Market Analysis and Forecast 2026-2032

22 December 2025193 pages

Choose your research edition.

Industry ResearchUlcerative Colitis Drugs Industry Research Report 2026126 pages · $2,950 USDIndustry Growth & TrendsGlobal Ulcerative Colitis Drugs Industry Growth and Trends Forecast to 2032113 pages · $3,450 USDMarket StructureGlobal Ulcerative Colitis Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Ulcerative Colitis Drugs Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Ulcerative Colitis Drugs Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Ulcerative Colitis Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Ulcerative Colitis Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Ulcerative Colitis Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Ulcerative Colitis Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Ulcerative Colitis Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Ulcerative Colitis Drugs include Takeda Pharmaceuticals Company, Sanofi, Johnson & Johnson, Novartis, Roche, Eli Lilly and Company, Pfizer, Ferring Pharmaceuticals and GSK, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Ulcerative Colitis Drugs, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Ulcerative Colitis Drugs, also provides the revenue of main regions and countries. Of the upcoming market potential for Ulcerative Colitis Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Ulcerative Colitis Drugs revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Ulcerative Colitis Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Ulcerative Colitis Drugs revenue, projected growth trends, production technology, application and end-user industry.

Ulcerative Colitis Drugs Segment by Company

Takeda Pharmaceuticals Company

Sanofi

Johnson & Johnson

Novartis

Roche

Eli Lilly and Company

Pfizer

Ferring Pharmaceuticals

GSK

Bayer

Amgen

AbbVie

AstraZeneca

MSD

InDeX Pharmaceuticals

Ulcerative Colitis Drugs Segment by Type

Oral

Injection

Ulcerative Colitis Drugs Segment by Application

Hospital

Drugs Stores

Ulcerative Colitis Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Ulcerative Colitis Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Ulcerative Colitis Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Ulcerative Colitis Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Ulcerative Colitis Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Ulcerative Colitis Drugs company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Ulcerative Colitis Drugs revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Ulcerative Colitis Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Oral Major Player Table 3. Injection Major Player Table 4. Global Ulcerative Colitis Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Hospital Major Player Table 6. Drugs Stores Major Player Table 7. Ulcerative Colitis Drugs Industry Trends Table 8. Ulcerative Colitis Drugs Industry Drivers Table 9. Ulcerative Colitis Drugs Industry Opportunities and Challenges Table 10. Ulcerative Colitis Drugs Industry Restraints Table 11. Global Ulcerative Colitis Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 12. Global Ulcerative Colitis Drugs Market Size by Region (2021-2026) & (US$ Million) Table 13. Global Ulcerative Colitis Drugs Market Share by Region (2021-2026) Table 14. Global Ulcerative Colitis Drugs Market Size by Region (2027-2032) & (US$ Million) Table 15. Global Ulcerative Colitis Drugs Market Share by Region (2027-2032) Table 16. Global Ulcerative Colitis Drugs Revenue by Players (US$ Million) & (2021-2026) Table 17. Global Ulcerative Colitis Drugs Revenue Market Share by Players (2021-2026) Table 18. Global Ulcerative Colitis Drugs Key Players Ranking, 2024 VS 2025 VS 2026 Table 19. Global Ulcerative Colitis Drugs Key Players Headquarters & Area Served Table 20. Global Ulcerative Colitis Drugs Players, Product Type & Application Table 21. Global Ulcerative Colitis Drugs Players Establishment Date Table 22. Global Players Market Concentration Ratio (CR5 and HHI) Table 23. Global Ulcerative Colitis Drugs by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 24. Global Ulcerative Colitis Drugs Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Ulcerative Colitis Drugs Revenue by Type (2021-2026) & (US$ Million) Table 26. Global Ulcerative Colitis Drugs Revenue by Type (2027-2032) & (US$ Million) Table 27. Global Ulcerative Colitis Drugs Revenue Market Share by Type (2021-2026) Table 28. Global Ulcerative Colitis Drugs Revenue Market Share by Type (2027-2032) Table 29. Global Ulcerative Colitis Drugs Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Ulcerative Colitis Drugs Revenue by Application (2021-2026) & (US$ Million) Table 31. Global Ulcerative Colitis Drugs Revenue by Application (2027-2032) & (US$ Million) Table 32. Global Ulcerative Colitis Drugs Revenue Market Share by Application (2021-2026) Table 33. Global Ulcerative Colitis Drugs Revenue Market Share by Application (2027-2032) Table 34. Takeda Pharmaceuticals Company Company Information Table 35. Takeda Pharmaceuticals Company Business Overview Table 36. Takeda Pharmaceuticals Company Ulcerative Colitis Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 37. Takeda Pharmaceuticals Company Ulcerative Colitis Drugs Product Portfolio Table 38. Takeda Pharmaceuticals Company Recent Development Table 39. Sanofi Company Information Table 40. Sanofi Business Overview Table 41. Sanofi Ulcerative Colitis Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 42. Sanofi Ulcerative Colitis Drugs Product Portfolio Table 43. Sanofi Recent Development Table 44. Johnson & Johnson Company Information Table 45. Johnson & Johnson Business Overview Table 46. Johnson & Johnson Ulcerative Colitis Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 47. Johnson & Johnson Ulcerative Colitis Drugs Product Portfolio Table 48. Johnson & Johnson Recent Development Table 49. Novartis Company Information Table 50. Novartis Business Overview Table 51. Novartis Ulcerative Colitis Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 52. Novartis Ulcerative Colitis Drugs Product Portfolio Table 53. Novartis Recent Development Table 54. Roche Company Information Table 55. Roche Business Overview Table 56. Roche Ulcerative Colitis Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 57. Roche Ulcerative Colitis Drugs Product Portfolio Table 58. Roche Recent Development Table 59. Eli Lilly and Company Company Information Table 60. Eli Lilly and Company Business Overview Table 61. Eli Lilly and Company Ulcerative Colitis Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 62. Eli Lilly and Company Ulcerative Colitis Drugs Product Portfolio Table 63. Eli Lilly and Company Recent Development Table 64. Pfizer Company Information Table 65. Pfizer Business Overview Table 66. Pfizer Ulcerative Colitis Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 67. Pfizer Ulcerative Colitis Drugs Product Portfolio Table 68. Pfizer Recent Development Table 69. Ferring Pharmaceuticals Company Information Table 70. Ferring Pharmaceuticals Business Overview Table 71. Ferring Pharmaceuticals Ulcerative Colitis Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 72. Ferring Pharmaceuticals Ulcerative Colitis Drugs Product Portfolio Table 73. Ferring Pharmaceuticals Recent Development Table 74. GSK Company Information Table 75. GSK Business Overview Table 76. GSK Ulcerative Colitis Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 77. GSK Ulcerative Colitis Drugs Product Portfolio Table 78. GSK Recent Development Table 79. Bayer Company Information Table 80. Bayer Business Overview Table 81. Bayer Ulcerative Colitis Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 82. Bayer Ulcerative Colitis Drugs Product Portfolio Table 83. Bayer Recent Development Table 84. Amgen Company Information Table 85. Amgen Business Overview Table 86. Amgen Ulcerative Colitis Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 87. Amgen Ulcerative Colitis Drugs Product Portfolio Table 88. Amgen Recent Development Table 89. AbbVie Company Information Table 90. AbbVie Business Overview Table 91. AbbVie Ulcerative Colitis Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 92. AbbVie Ulcerative Colitis Drugs Product Portfolio Table 93. AbbVie Recent Development Table 94. AstraZeneca Company Information Table 95. AstraZeneca Business Overview Table 96. AstraZeneca Ulcerative Colitis Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 97. AstraZeneca Ulcerative Colitis Drugs Product Portfolio Table 98. AstraZeneca Recent Development Table 99. MSD Company Information Table 100. MSD Business Overview Table 101. MSD Ulcerative Colitis Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 102. MSD Ulcerative Colitis Drugs Product Portfolio Table 103. MSD Recent Development Table 104. InDeX Pharmaceuticals Company Information Table 105. InDeX Pharmaceuticals Business Overview Table 106. InDeX Pharmaceuticals Ulcerative Colitis Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 107. InDeX Pharmaceuticals Ulcerative Colitis Drugs Product Portfolio Table 108. InDeX Pharmaceuticals Recent Development Table 109. North America Ulcerative Colitis Drugs Revenue by Type (2021-2026) & (US$ Million) Table 110. North America Ulcerative Colitis Drugs Revenue by Type (2027-2032) & (US$ Million) Table 111. North America Ulcerative Colitis Drugs Revenue by Application (2021-2026) & (US$ Million) Table 112. North America Ulcerative Colitis Drugs Revenue by Application (2027-2032) & (US$ Million) Table 113. North America Ulcerative Colitis Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 114. North America Ulcerative Colitis Drugs Revenue by Country (2021-2026) & (US$ Million) Table 115. North America Ulcerative Colitis Drugs Revenue by Country (US$ Million) & (2027-2032) Table 116. Europe Ulcerative Colitis Drugs Revenue by Type (2021-2026) & (US$ Million) Table 117. Europe Ulcerative Colitis Drugs Revenue by Type (2027-2032) & (US$ Million) Table 118. Europe Ulcerative Colitis Drugs Revenue by Application (2021-2026) & (US$ Million) Table 119. Europe Ulcerative Colitis Drugs Revenue by Application (2027-2032) & (US$ Million) Table 120. Europe Ulcerative Colitis Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 121. Europe Ulcerative Colitis Drugs Revenue by Country (2021-2026) & (US$ Million) Table 122. Europe Ulcerative Colitis Drugs Revenue by Country (US$ Million) & (2027-2032) Table 123. China Ulcerative Colitis Drugs Revenue by Type (2021-2026) & (US$ Million) Table 124. China Ulcerative Colitis Drugs Revenue by Type (2027-2032) & (US$ Million) Table 125. China Ulcerative Colitis Drugs Revenue by Application (2021-2026) & (US$ Million) Table 126. China Ulcerative Colitis Drugs Revenue by Application (2027-2032) & (US$ Million) Table 127. Asia Ulcerative Colitis Drugs Revenue by Type (2021-2026) & (US$ Million) Table 128. Asia Ulcerative Colitis Drugs Revenue by Type (2027-2032) & (US$ Million) Table 129. Asia Ulcerative Colitis Drugs Revenue by Application (2021-2026) & (US$ Million) Table 130. Asia Ulcerative Colitis Drugs Revenue by Application (2027-2032) & (US$ Million) Table 131. Asia Ulcerative Colitis Drugs Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 132. Asia Ulcerative Colitis Drugs Revenue by Region (US$ Million) & (2021-2026) Table 133. Asia Ulcerative Colitis Drugs Revenue by Region (US$ Million) & (2027-2032) Table 134. SAMEA Ulcerative Colitis Drugs Revenue by Type (2021-2026) & (US$ Million) Table 135. SAMEA Ulcerative Colitis Drugs Revenue by Type (2027-2032) & (US$ Million) Table 136. SAMEA Ulcerative Colitis Drugs Revenue by Application (2021-2026) & (US$ Million) Table 137. SAMEA Ulcerative Colitis Drugs Revenue by Application (2027-2032) & (US$ Million) Table 138. SAMEA Ulcerative Colitis Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 139. SAMEA Ulcerative Colitis Drugs Revenue by Country (2021-2026) & (US$ Million) Table 140. SAMEA Ulcerative Colitis Drugs Revenue by Country (US$ Million) & (2027-2032) Table 141. Research Programs/Design for This Report Table 142. Authors List of This Report Table 143. Secondary Sources Table 144. Primary Sources List of Figures Figure 1. Ulcerative Colitis Drugs Image Figure 2. Global Ulcerative Colitis Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Ulcerative Colitis Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 4. Oral Image Figure 5. Injection Image Figure 6. Global Ulcerative Colitis Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Ulcerative Colitis Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 8. Hospital Image Figure 9. Drugs Stores Image Figure 10. Global Ulcerative Colitis Drugs Market Size (US$ Million) & (2021-2032) Figure 11. Global Ulcerative Colitis Drugs Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Ulcerative Colitis Drugs Market Share by Region: 2021 VS 2025 VS 2032 Figure 13. Global Ulcerative Colitis Drugs Players Revenue Share Top 10 and Top 5 in 2025 Figure 14. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 15. Global Ulcerative Colitis Drugs Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Ulcerative Colitis Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Ulcerative Colitis Drugs Revenue Market Share by Type (2021-2032) Figure 18. Global Ulcerative Colitis Drugs Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Ulcerative Colitis Drugs Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 20. Global Ulcerative Colitis Drugs Revenue Market Share by Application (2021-2032) Figure 21. North America Ulcerative Colitis Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 22. North America Ulcerative Colitis Drugs Revenue Share by Type (2021-2032) Figure 23. North America Ulcerative Colitis Drugs Revenue Share by Application (2021-2032) Figure 24. North America Ulcerative Colitis Drugs Revenue Share by Country (2021-2032) Figure 25. United States Ulcerative Colitis Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 26. Canada Ulcerative Colitis Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Mexico Ulcerative Colitis Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Europe Ulcerative Colitis Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 29. Europe Ulcerative Colitis Drugs Revenue Share by Type (2021-2032) Figure 30. Europe Ulcerative Colitis Drugs Revenue Share by Application (2021-2032) Figure 31. Europe Ulcerative Colitis Drugs Revenue Share by Country (2021-2032) Figure 32. Germany Ulcerative Colitis Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. France Ulcerative Colitis Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. U.K. Ulcerative Colitis Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. Italy Ulcerative Colitis Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Spain Ulcerative Colitis Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Russia Ulcerative Colitis Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Netherlands Ulcerative Colitis Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Nordic Countries Ulcerative Colitis Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. China Ulcerative Colitis Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 41. China Ulcerative Colitis Drugs Revenue Share by Type (2021-2032) Figure 42. China Ulcerative Colitis Drugs Revenue Share by Application (2021-2032) Figure 43. Asia Ulcerative Colitis Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. Asia Ulcerative Colitis Drugs Revenue Share by Type (2021-2032) Figure 45. Asia Ulcerative Colitis Drugs Revenue Share by Application (2021-2032) Figure 46. Asia Ulcerative Colitis Drugs Revenue Share by Region (2021-2032) Figure 47. Japan Ulcerative Colitis Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 48. South Korea Ulcerative Colitis Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. India Ulcerative Colitis Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. Australia Ulcerative Colitis Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Taiwan Ulcerative Colitis Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Southeast Asia Ulcerative Colitis Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. SAMEA Ulcerative Colitis Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 54. SAMEA Ulcerative Colitis Drugs Revenue Share by Type (2021-2032) Figure 55. SAMEA Ulcerative Colitis Drugs Revenue Share by Application (2021-2032) Figure 56. SAMEA Ulcerative Colitis Drugs Revenue Share by Country (2021-2032) Figure 57. Brazil Ulcerative Colitis Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. Argentina Ulcerative Colitis Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Chile Ulcerative Colitis Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Colombia Ulcerative Colitis Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Peru Ulcerative Colitis Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Saudi Arabia Ulcerative Colitis Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Israel Ulcerative Colitis Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. UAE Ulcerative Colitis Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Turkey Ulcerative Colitis Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Iran Ulcerative Colitis Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Egypt Ulcerative Colitis Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Years Considered Figure 69. Research Process Figure 70. Key Executives Interviewed

Scope & coverage.

Types
  • Oral
  • Injection
Applications
  • Hospital
  • Drugs Stores
Companies covered
  • Takeda Pharmaceuticals Company
  • Sanofi
  • Johnson & Johnson
  • Novartis
  • Roche
  • Eli Lilly and Company
  • Pfizer
  • Ferring Pharmaceuticals
  • GSK
  • Bayer
  • Amgen
  • AbbVie
  • AstraZeneca
  • MSD
  • InDeX Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Ulcerative Colitis Drugs Market by Type
  3. 1.2.1 Global Ulcerative Colitis Drugs Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Oral
  5. 1.2.3 Injection
  6. 1.3 Ulcerative Colitis Drugs Market by Application
  7. 1.3.1 Global Ulcerative Colitis Drugs Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Hospital
  9. 1.3.3 Drugs Stores
  10. 1.4 Assumptions and Limitations
  11. 1.5 Study Goals and Objectives
2 Ulcerative Colitis Drugs Market Dynamics
  1. 2.1 Ulcerative Colitis Drugs Industry Trends
  2. 2.2 Ulcerative Colitis Drugs Industry Drivers
  3. 2.3 Ulcerative Colitis Drugs Industry Opportunities and Challenges
  4. 2.4 Ulcerative Colitis Drugs Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Ulcerative Colitis Drugs Market Perspective (2021-2032)
  2. 3.2 Global Ulcerative Colitis Drugs Growth Trends by Region
  3. 3.2.1 Global Ulcerative Colitis Drugs Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Ulcerative Colitis Drugs Market Size by Region (2021-2026)
  5. 3.2.3 Global Ulcerative Colitis Drugs Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Ulcerative Colitis Drugs Revenue by Players
  2. 4.1.1 Global Ulcerative Colitis Drugs Revenue by Players (2021-2026)
  3. 4.1.2 Global Ulcerative Colitis Drugs Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Ulcerative Colitis Drugs Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Ulcerative Colitis Drugs Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Ulcerative Colitis Drugs Key Players Headquarters & Area Served
  7. 4.4 Global Ulcerative Colitis Drugs Players, Product Type & Application
  8. 4.5 Global Ulcerative Colitis Drugs Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Ulcerative Colitis Drugs Market CR5 and HHI
  11. 4.6.3 2025 Ulcerative Colitis Drugs Tier 1, Tier 2, and Tier 3
5 Ulcerative Colitis Drugs Market Size by Type
  1. 5.1 Global Ulcerative Colitis Drugs Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Ulcerative Colitis Drugs Revenue by Type (2021-2032)
  3. 5.3 Global Ulcerative Colitis Drugs Revenue Market Share by Type (2021-2032)
6 Ulcerative Colitis Drugs Market Size by Application
  1. 6.1 Global Ulcerative Colitis Drugs Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Ulcerative Colitis Drugs Revenue by Application (2021-2032)
  3. 6.3 Global Ulcerative Colitis Drugs Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Takeda Pharmaceuticals Company
  2. 7.1.1 Takeda Pharmaceuticals Company Company Information
  3. 7.1.2 Takeda Pharmaceuticals Company Business Overview
  4. 7.1.3 Takeda Pharmaceuticals Company Ulcerative Colitis Drugs Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Takeda Pharmaceuticals Company Ulcerative Colitis Drugs Product Portfolio
  6. 7.1.5 Takeda Pharmaceuticals Company Recent Developments
  7. 7.2 Sanofi
  8. 7.2.1 Sanofi Company Information
  9. 7.2.2 Sanofi Business Overview
  10. 7.2.3 Sanofi Ulcerative Colitis Drugs Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Sanofi Ulcerative Colitis Drugs Product Portfolio
  12. 7.2.5 Sanofi Recent Developments
  13. 7.3 Johnson & Johnson
  14. 7.3.1 Johnson & Johnson Company Information
  15. 7.3.2 Johnson & Johnson Business Overview
  16. 7.3.3 Johnson & Johnson Ulcerative Colitis Drugs Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Johnson & Johnson Ulcerative Colitis Drugs Product Portfolio
  18. 7.3.5 Johnson & Johnson Recent Developments
  19. 7.4 Novartis
  20. 7.4.1 Novartis Company Information
  21. 7.4.2 Novartis Business Overview
  22. 7.4.3 Novartis Ulcerative Colitis Drugs Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Novartis Ulcerative Colitis Drugs Product Portfolio
  24. 7.4.5 Novartis Recent Developments
  25. 7.5 Roche
  26. 7.5.1 Roche Company Information
  27. 7.5.2 Roche Business Overview
  28. 7.5.3 Roche Ulcerative Colitis Drugs Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Roche Ulcerative Colitis Drugs Product Portfolio
  30. 7.5.5 Roche Recent Developments
  31. 7.6 Eli Lilly and Company
  32. 7.6.1 Eli Lilly and Company Company Information
  33. 7.6.2 Eli Lilly and Company Business Overview
  34. 7.6.3 Eli Lilly and Company Ulcerative Colitis Drugs Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Eli Lilly and Company Ulcerative Colitis Drugs Product Portfolio
  36. 7.6.5 Eli Lilly and Company Recent Developments
  37. 7.7 Pfizer
  38. 7.7.1 Pfizer Company Information
  39. 7.7.2 Pfizer Business Overview
  40. 7.7.3 Pfizer Ulcerative Colitis Drugs Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Pfizer Ulcerative Colitis Drugs Product Portfolio
  42. 7.7.5 Pfizer Recent Developments
  43. 7.8 Ferring Pharmaceuticals
  44. 7.8.1 Ferring Pharmaceuticals Company Information
  45. 7.8.2 Ferring Pharmaceuticals Business Overview
  46. 7.8.3 Ferring Pharmaceuticals Ulcerative Colitis Drugs Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Ferring Pharmaceuticals Ulcerative Colitis Drugs Product Portfolio
  48. 7.8.5 Ferring Pharmaceuticals Recent Developments
  49. 7.9 GSK
  50. 7.9.1 GSK Company Information
  51. 7.9.2 GSK Business Overview
  52. 7.9.3 GSK Ulcerative Colitis Drugs Revenue and Gross Margin (2021-2026)
  53. 7.9.4 GSK Ulcerative Colitis Drugs Product Portfolio
  54. 7.9.5 GSK Recent Developments
  55. 7.10 Bayer
  56. 7.10.1 Bayer Company Information
  57. 7.10.2 Bayer Business Overview
  58. 7.10.3 Bayer Ulcerative Colitis Drugs Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Bayer Ulcerative Colitis Drugs Product Portfolio
  60. 7.10.5 Bayer Recent Developments
  61. 7.11 Amgen
  62. 7.11.1 Amgen Company Information
  63. 7.11.2 Amgen Business Overview
  64. 7.11.3 Amgen Ulcerative Colitis Drugs Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Amgen Ulcerative Colitis Drugs Product Portfolio
  66. 7.11.5 Amgen Recent Developments
  67. 7.12 AbbVie
  68. 7.12.1 AbbVie Company Information
  69. 7.12.2 AbbVie Business Overview
  70. 7.12.3 AbbVie Ulcerative Colitis Drugs Revenue and Gross Margin (2021-2026)
  71. 7.12.4 AbbVie Ulcerative Colitis Drugs Product Portfolio
  72. 7.12.5 AbbVie Recent Developments
  73. 7.13 AstraZeneca
  74. 7.13.1 AstraZeneca Company Information
  75. 7.13.2 AstraZeneca Business Overview
  76. 7.13.3 AstraZeneca Ulcerative Colitis Drugs Revenue and Gross Margin (2021-2026)
  77. 7.13.4 AstraZeneca Ulcerative Colitis Drugs Product Portfolio
  78. 7.13.5 AstraZeneca Recent Developments
  79. 7.14 MSD
  80. 7.14.1 MSD Company Information
  81. 7.14.2 MSD Business Overview
  82. 7.14.3 MSD Ulcerative Colitis Drugs Revenue and Gross Margin (2021-2026)
  83. 7.14.4 MSD Ulcerative Colitis Drugs Product Portfolio
  84. 7.14.5 MSD Recent Developments
  85. 7.15 InDeX Pharmaceuticals
  86. 7.15.1 InDeX Pharmaceuticals Company Information
  87. 7.15.2 InDeX Pharmaceuticals Business Overview
  88. 7.15.3 InDeX Pharmaceuticals Ulcerative Colitis Drugs Revenue and Gross Margin (2021-2026)
  89. 7.15.4 InDeX Pharmaceuticals Ulcerative Colitis Drugs Product Portfolio
  90. 7.15.5 InDeX Pharmaceuticals Recent Developments
8 North America
  1. 8.1 North America Ulcerative Colitis Drugs Revenue (2021-2032)
  2. 8.2 North America Ulcerative Colitis Drugs Revenue by Type (2021-2032)
  3. 8.2.1 North America Ulcerative Colitis Drugs Revenue by Type (2021-2026)
  4. 8.2.2 North America Ulcerative Colitis Drugs Revenue by Type (2027-2032)
  5. 8.3 North America Ulcerative Colitis Drugs Revenue Share by Type (2021-2032)
  6. 8.4 North America Ulcerative Colitis Drugs Revenue by Application (2021-2032)
  7. 8.4.1 North America Ulcerative Colitis Drugs Revenue by Application (2021-2026)
  8. 8.4.2 North America Ulcerative Colitis Drugs Revenue by Application (2027-2032)
  9. 8.5 North America Ulcerative Colitis Drugs Revenue Share by Application (2021-2032)
  10. 8.6 North America Ulcerative Colitis Drugs Revenue by Country
  11. 8.6.1 North America Ulcerative Colitis Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Ulcerative Colitis Drugs Revenue by Country (2021-2026)
  13. 8.6.3 North America Ulcerative Colitis Drugs Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Ulcerative Colitis Drugs Revenue (2021-2032)
  2. 9.2 Europe Ulcerative Colitis Drugs Revenue by Type (2021-2032)
  3. 9.2.1 Europe Ulcerative Colitis Drugs Revenue by Type (2021-2026)
  4. 9.2.2 Europe Ulcerative Colitis Drugs Revenue by Type (2027-2032)
  5. 9.3 Europe Ulcerative Colitis Drugs Revenue Share by Type (2021-2032)
  6. 9.4 Europe Ulcerative Colitis Drugs Revenue by Application (2021-2032)
  7. 9.4.1 Europe Ulcerative Colitis Drugs Revenue by Application (2021-2026)
  8. 9.4.2 Europe Ulcerative Colitis Drugs Revenue by Application (2027-2032)
  9. 9.5 Europe Ulcerative Colitis Drugs Revenue Share by Application (2021-2032)
  10. 9.6 Europe Ulcerative Colitis Drugs Revenue by Country
  11. 9.6.1 Europe Ulcerative Colitis Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Ulcerative Colitis Drugs Revenue by Country (2021-2026)
  13. 9.6.3 Europe Ulcerative Colitis Drugs Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Ulcerative Colitis Drugs Revenue (2021-2032)
  2. 10.2 China Ulcerative Colitis Drugs Revenue by Type (2021-2032)
  3. 10.2.1 China Ulcerative Colitis Drugs Revenue by Type (2021-2026)
  4. 10.2.2 China Ulcerative Colitis Drugs Revenue by Type (2027-2032)
  5. 10.3 China Ulcerative Colitis Drugs Revenue Share by Type (2021-2032)
  6. 10.4 China Ulcerative Colitis Drugs Revenue by Application (2021-2032)
  7. 10.4.1 China Ulcerative Colitis Drugs Revenue by Application (2021-2026)
  8. 10.4.2 China Ulcerative Colitis Drugs Revenue by Application (2027-2032)
  9. 10.5 China Ulcerative Colitis Drugs Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Ulcerative Colitis Drugs Revenue (2021-2032)
  2. 11.2 Asia Ulcerative Colitis Drugs Revenue by Type (2021-2032)
  3. 11.2.1 Asia Ulcerative Colitis Drugs Revenue by Type (2021-2026)
  4. 11.2.2 Asia Ulcerative Colitis Drugs Revenue by Type (2027-2032)
  5. 11.3 Asia Ulcerative Colitis Drugs Revenue Share by Type (2021-2032)
  6. 11.4 Asia Ulcerative Colitis Drugs Revenue by Application (2021-2032)
  7. 11.4.1 Asia Ulcerative Colitis Drugs Revenue by Application (2021-2026)
  8. 11.4.2 Asia Ulcerative Colitis Drugs Revenue by Application (2027-2032)
  9. 11.5 Asia Ulcerative Colitis Drugs Revenue Share by Application (2021-2032)
  10. 11.6 Asia Ulcerative Colitis Drugs Revenue by Country
  11. 11.6.1 Asia Ulcerative Colitis Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Ulcerative Colitis Drugs Revenue by Country (2021-2026)
  13. 11.6.3 Asia Ulcerative Colitis Drugs Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Ulcerative Colitis Drugs Revenue (2021-2032)
  2. 12.2 SAMEA Ulcerative Colitis Drugs Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Ulcerative Colitis Drugs Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Ulcerative Colitis Drugs Revenue by Type (2027-2032)
  5. 12.3 SAMEA Ulcerative Colitis Drugs Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Ulcerative Colitis Drugs Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Ulcerative Colitis Drugs Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Ulcerative Colitis Drugs Revenue by Application (2027-2032)
  9. 12.5 SAMEA Ulcerative Colitis Drugs Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Ulcerative Colitis Drugs Revenue by Country
  11. 12.6.1 SAMEA Ulcerative Colitis Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Ulcerative Colitis Drugs Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Ulcerative Colitis Drugs Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst